Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2002

View Archived Issues

Viventia options anticancer hybridomas from M.D. Cancer Center

VaxGen awarded government contract for anthrax vaccine

Clinical section of Vitrase NDA submitted

DAC:GLP-1 phase I results delayed

Cortex and Servier expand Ampakine research collaboration

IL-21 added to ZymoGenetics development pipeline

Safety and pharmacokinetics of LY-451395 in healthy volunteers

Glutamate mglu5-selective antagonist may potentiate activity of conventional AEDs

Pimecrolimus a highlight of this year's EADV congress

Antiepileptic drugs in bipolar disorder

Olanzapine/fluoxetine combination in major depression

Two series of PPARalpha and/or PPARgamma agonists identified at Dr. Reddy's

Inhibitors of TGF-beta signaling pathway described in GSK patent

Pharmacia evaluating inhibitors of viral DNA polymerase

Novel GlyT-2 inhibitors and their use in psychosis, pain, epilepsy, etc.

Potential antidiabetic thiazolidinones prepared and tested at Merck

Merck patent covers novel alpha1A-adrenoceptor antagonists and their use in BPH

Novel beta3-adrenoceptor agonists under study at BMS

VRC-3375 used as a lead to develop more potent antibacterial PDF inhibitors

Neuropharmacological profile of SLV-313, a dual D2 antagonist/5-HT1A agonist

Korean research demonstrates stimulation of hair growth following culture with epigallocatechin

Timing of single doses of FK-506 important for limb allograft success

Thrombin-related peptide accelerates fracture healing in first human trial

Karo Bio and Bristol-Myers Squibb extend obesity collaboration

Initiation of phase II Triapine trial in head and neck cancer

Enrollment completed in phase II Theratope trial for metastatic colorectal cancer

Fuzeon, the first HIV fusion inhibitor, will receive a priority review at the FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...